Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’...

nork Porta, C
Argitaratua 2010

Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non‐musicians: the importance of silence

nork Bernardi, L, Porta, C, Sleight, P
Argitaratua 2006

Sunitinib re-challenge in advanced renal-cell carcinoma

nork Porta, C, Paglino, C, Grünwald, V
Argitaratua izan da Br J Cancer (2014)

Immunoadherence and complement in cancer-bearing mice.

nork Porta, C., Villa, M. L., Clerici, E.
Argitaratua 1978

Inhibition of protein kinase C-alpha isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure.

nork La Porta, C. A., Dolfini, E., Comolli, R.
Argitaratua 1998

Nuclear factors specifically bind to upstream sequences of a Xenopus laevis ribosomal protein gene promoter.

nork Carnevali, F, La Porta, C, Ilardi, V, Beccari, E
Argitaratua 1989

Effective Time Management: Surgery, Research, Service, Travel, Fitness, and Family

nork Porta, C. Rees, Anderson, Michael R., Steele, Scott R.
Argitaratua 2013

Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients.

nork Moroni, M., Porta, C., Gualtieri, G., Nastasi, G., Tinelli, C.
Argitaratua 1996

Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?

nork Bernardi, L, Passino, C, Porta, C, Anesi, E, Palladini, G, Merlini, G
Argitaratua 2002

Repeat partial nephrectomy for recurrence of Von Hippel-Lindau-related renal cell carcinoma in an autotransplanted kidney

nork Perri, D., Marchioro, G., Bondonno, G., Maso, G., Porta, C., Volpe, A.
Argitaratua izan da Urol Case Rep (2020)

Comparing comparators: a look at control arms in kidney cancer studies over the years

nork Bracarda, S, Porta, C, Sisani, M, Marrocolo, F, Paglino, C, Hamzaj, A, D Buono, S, Sternberg, C N
Argitaratua izan da Br J Cancer (2015)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

nork Procopio, G, Verzoni, E, Bracarda, S, Ricci, S, Sacco, C, Ridolfi, L, Porta, C, Miceli, R, Zilembo, N, Bajetta, E
Argitaratua 2011

Nursing practice and global refugee migration: initial impressions from an Intergovernmental-Academic Partnership

nork Bampoh, V., Thongkhamkitcharoen, M., Dicker, S., Dalal, W., Frerich, E., Mann, E., Porta, C., Siddons, N., Stauffer, WM, Hoffman, S.J.
Argitaratua izan da Int Nurs Rev (2020)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

nork Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Argitaratua 2012

Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

nork Quaquarini, E., D'Ambrosio, D., Sottotetti, F., Gallivanone, F., Hodolic, M., Baiardi, P., Palumbo, R., Vellani, C., Canevari, C., Bernardo, A., Castiglioni, I., Porta, C., Trifirò, G.
Argitaratua izan da Contrast Media Mol Imaging (2019)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

nork Aeppli, S., Schmaus, M., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B.I., Schmidinger, M., Sternberg, C.N., Rothermundt, C., Putora, P.M.
Argitaratua izan da ESMO Open (2021)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

nork Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
Argitaratua izan da Br J Cancer (2015)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

nork Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O. Arén, Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B.
Argitaratua izan da N Engl J Med (2018)